Importance of biological clock epigenetics in the manifestation of polycystic ovary syndrome

Abstract

In recent times, the incidence of polycystic ovary syndrome (PCOS) increases at an alarming rate. It is ascribed to the metabolic and endocrine imbalance, which subsequently adversely impacts the fertility of women. Growing evidence indicates the crucial role of circadian biology in the development and progression of PCOS. Here, we describe the role of epigenetic machinery related to circadian genes (Clock, Bmal, Per, and Cry) on insulin resistance and hyperandrogenism components of the PCOS. We comprehensively discuss the interconnection between the genetics of circadian rhythm and PCOS pathophysiology. Deeper insights into the epigenetic changes of circadian genes may open new routes for the epigenetic regulation of ovarian physiology and PCOS.

References

1. References
2. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Prim. 2016;2.
3. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007;31:S8–13.
4. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.
5. Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (Sao Paulo). 2015 Nov;70(11):765–9.
6. Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2(1):14.
7. Sahar S, Sassone-Corsi P. Regulation of metabolism: the circadian clock dictates the time. Trends Endocrinol Metab. 2012;23(1):1–8.
8. Dyar KA, Ciciliot S, Wright LE, Biensø RS, Tagliazucchi GM, Patel VR, et al. Muscle insulin sensitivity and glucose metabolism are controlled by the intrinsic muscle clock. Mol Metab. 2014;3(1):29–41.
9. Spinedi E, Cardinali DP. The polycystic ovary syndrome and the metabolic syndrome: a possible chronobiotic-cytoprotective adjuvant therapy. Int J Endocrinol. 2018;2018.
10. Lim AJR, Indran IR, Kramer MS, Yong E. Phenotypic spectrum of polycystic ovary syndrome and their relationship to the circadian biomarkers, melatonin and cortisol. Endocrinol diabetes Metab. 2019;2(3):e00047.
11. Padmanabhan V, Veiga-Lopez A. Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming. In: Seminars in reproductive medicine. © Thieme Medical Publishers; 2011. p. 173–86.
12. Amaral FG do, Castrucci AM, Cipolla‐Neto J, Poletini MO, Mendez N, Richter HG, et al. Environmental control of biological rhythms: effects on development, fertility and metabolism. J Neuroendocrinol. 2014;26(9):603–12.
13. Sellix MT, Murphy ZC, Menaker M. Excess androgen during puberty disrupts circadian organization in female rats. Endocrinology. 2013;154(4):1636–47.
14. Sellix MT. Circadian clock function in the mammalian ovary. J Biol Rhythms. 2015;30(1):7–19.
15. Martin-Gronert MS, Ozanne SE. Programming of appetite and type 2 diabetes. Early Hum Dev. 2005;81(12):981–8.
16. Wazen RM, Kuroda S, Nishio C, Sellin K, Brunski JB, Nanci A. NIH Public Access. 2014;8(9):1385–95.
17. Xita N, Tsatsoulis A. Fetal Programming of Polycystic Ovary Syndrome by Androgen Excess: Evidence from Experimental, Clinical, and Genetic Association Studies. J Clin Endocrinol Metab. 2006;91(5):1660–6.
18. Li Z, Huang H. Epigenetic abnormality: A possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses. 2008;70(3):638–42.
19. Manenschijn L, Van Kruysbergen RGPM, De Jong FH, Koper JW, Van Rossum EFC. Shift work at young age is associated with elevated long-term cortisol levels and body mass index. J Clin Endocrinol Metab. 2011;96(11):1862–5.
20. Milagro FI, Gómez-Abellán P, Campión J, Martínez JA, Ordovás JM, Garaulet M. CLOCK, PER2 and BMAL1 DNA methylation: Association with obesity and metabolic syndrome characteristics and monounsaturated fat intake. Chronobiol Int. 2012;29(9):1180–94.
21. Foley JF. Against the CLOCK. Sci Signal. 2008;1(30):ec270–ec270.
22. Zhou B, Zhang Y, Zhang F, Xia Y, Liu J, Huang R, et al. CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity by SIRT1. Hepatology. 2014;59(6):2196–206.
23. Sathyapalan T, David R, Gooderham NJ, Atkin SL. Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Sci Rep. 2015;5(November):1–8.
24. Xu J, Bao X, Peng Z, Wang L, Du L, Niu W, et al. Comprehensive analysis of genome-wide DNA methylation across human polycystic ovary syndrome ovary granulosa cell. Oncotarget. 2016;7(19):27899–909.
25. Ilie IR, Georgescu CE. Polycystic ovary syndrome-epigenetic mechanisms and aberrant microRNA. In: Advances in clinical chemistry. Elsevier; 2015. p. 25–45.
26. Xie Z, Huang G, Wang Z, Luo S, Zheng P, Zhou Z. Epigenetic regulation of Toll-like receptors and its roles in type 1 diabetes. J Mol Med. 2018;96(8):741–51.
27. Shamsi MB, Firoz AS, Imam SN, Alzaman N, Samman MA. Epigenetics of human diseases and scope in future therapeutics. J Taibah Univ Med Sci. 2017;12(3):205–11.
28. Kokosar M, Benrick A, Perfilyev A, Fornes R, Nilsson E, Maliqueo M, et al. Epigenetic and Transcriptional Alterations in Human Adipose Tissue of Polycystic Ovary Syndrome. Sci Rep. 2016;6(September 2015):1–17.
29. Yu YY, Sun CX, Liu YK, Li Y, Wang L, Zhang W. Genome-wide screen of ovary-specific DNA methylation in polycystic ovary syndrome. Fertil Steril. 2015;104(1):145-153.e6.
30. Shen H, Qiu L, Zhang Z, Qin Y, Cao C, Di W. Genome-Wide Methylated DNA Immunoprecipitation Analysis of Patients with Polycystic Ovary Syndrome. PLoS One. 2013;8(5):e64801.
31. Qu F, Wang FF, Yin R, Ding GL, El-prince M, Gao Q, et al. A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: Hyperandrogenism induces epigenetic alterations in the granulosa cells. J Mol Med. 2012;90(8):911–23.
32. Sang Q, Li X, Wang H, Wang H, Zhang S, Feng R, et al. Quantitative methylation level of the EPHX1 promoter in peripheral blood DNA is associated with polycystic ovary syndrome. PLoS One. 2014;9(2):1–7.
33. Chrun ES, Modolo F, Daniel FI. Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathol Res Pract. 2017;213(11):1329–39.
34. Chen Y, Fang S. Potential genetic polymorphisms predicting polycystic ovary syndrome. Endocr Connect. 2018;EC-18-0121.
35. Jansen E, Laven JSE, Dommerholt HBR, Polman J, van Rijt C, van den Hurk C, et al. Abnormal Gene Expression Profiles in Human Ovaries from Polycystic Ovary Syndrome Patients. Mol Endocrinol. 2004;18(12):3050–63.
36. Wood JR, Nelson-Degrave VL, Jansen E, McAllister JM, Mosselman S, Strauss JF. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics. 2005;20(3):233–43.
37. Tian Y, Wong VWS, Wong GLH, Yang W, Sun H, Shen J, et al. Histone deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res. 2015;75(22):4803–16.
38. Ye J. Improving insulin sensitivity with HDAC inhibitor. Diabetes. 2013;62(3):685–7.
39. Balcerczyk A, Chriett S, Pirola L. Insulin Action , Insulin Resistance , and Their Link to Histone Acetylation. In p. 1–22.
40. Christensen D, Dahllof M. . Mol Med. 2011;17(5–6):1.
41. Reza MI, Goel D, Rahman Z, Aamer S. Microrna and Rna Binding Proteins: the Posttranscriptional Regulators of Foxo Expression. J Crit Rev. 2018;5(2):1.
42. Klotz CL, Jena F. Posttranscriptional regulation of FOXO expression : microRNAs and beyond. Br J Pharmacol. 2016;1–19.
43. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005 Jan;433:769.
44. Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts. 2017 Dec;8(5–6):203–12.
45. Hossain MM, Cao M, Wang Q, Kim JY, Schellander K, Tesfaye D, et al. Altered expression of miRNAs in a dihydrotestosterone-induced rat PCOS model. J Ovarian Res. 2013;6(1):1.
46. Naji M, Aleyasin A, Nekoonam S, Arefian E, Mahdian R, Amidi F. Differential Expression of miR-93 and miR-21 in Granulosa Cells and Follicular Fluid of Polycystic Ovary Syndrome Associating with Different Phenotypes. Sci Rep. 2017;7(1):1–14.
47. Sang Q, Yao Z, Wang H, Feng R, Wang H, Zhao X, et al. Identification of MicroRNAs in human follicular fluid: Characterization of MicroRNAs that govern steroidogenesis in vitro and are associated with polycystic ovary syndrome in vivo. J Clin Endocrinol Metab. 2013;98(7):3068–79.
48. Scalici E, Traver S, Mullet T, Molinari N, Ferrières A, Brunet C, et al. Circulating microRNAs in follicular fluid, powerful tools to explore in vitro fertilization process. Sci Rep. 2016;6(April):1–10.
49. Stubbs SA, Stark J, Dilworth SM, Franks S, Hardy K. Abnormal preantral folliculogenesis in polycystic ovaries is associated with increased granulosa cell division. J Clin Endocrinol Metab. 2007;92(11):4418–26.
50. Jiang L, Huang J, Li L, Chen Y, Chen X, Zhao X, et al. MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome. J Clin Endocrinol Metab. 2015;100(5):E729–38.
51. McAllister JM, Legro RS, Modi BP, Strauss III JF. Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab. 2015;26(3):118–24.
52. Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26(2):251–82.
53. S�rensen AE, Wissing ML, Englund ALM, Dalgaard LT. MicroRNA species in follicular fluid associating with polycystic ovary syndrome and related intermediary phenotypes. J Clin Endocrinol Metab. 2016;101(4):1579–89.
54. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science (80- ). 1996;271(5249):665–70.
55. De Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner. J Biol Chem. 2004;279(17):17070–8.
56. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860.
57. Vivacqua A, Marco P De, Belfiore A, Maggiolini M. Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer. Curr Pharm Des. 2017;23(25):3658–66.
58. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol. 2007;21(11):2785–94.
59. Chakraborty C, Doss CGP, Bandyopadhyay S, Agoramoorthy G. Influence of miRNA in insulin signaling pathway and insulin resistance: micro‐molecules with a major role in type‐2 diabetes. Wiley Interdiscip Rev RNA. 2014;5(5):697–712.
60. Wang T, Li F, Tang S. MiR-30a upregulates BCL2A1, IER3 and cyclináD2 expression by targeting FOXL2. Oncol Lett. 2015;9(2):967–71.
61. Yuan W-N, Tan L. MicroRNA-320 inhibits insulin resistance in patients with PCOS through regulating ERK1/2 signaling pathway. Biomed Res. 2017;28(11):4946–9.
62. Jordan SD, Krüger M, Willmes DM, Redemann N, Wunderlich FT, Brönneke HS, et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol. 2011 Mar;13:434.
63. Zhu H, Shyh-Chang N, Segrè A V, Shinoda G, Shah SP, Einhorn WS, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147(1):81–94.
64. Shi ZM, Wang XF, Qian X, Tao T, Wang L, Chen QD, et al. MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. Rna. 2013;19(4):552–60.
65. Wu H-L, Heneidi S, Chuang T-Y, Diamond MP, Layman LC, Azziz R, et al. The Expression of the miR-25/93/106b Family of Micro-RNAs in the Adipose Tissue of Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2014 Dec;99(12):E2754–61.
66. Chen YH, Heneidi S, Lee JM, Layman LC, Stepp DW, Gamboa GM, et al. Mirna-93 inhibits glut4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes. 2013;62(7):2278–86.
67. Ling H-Y, Hu B, Hu X-B, Zhong J, Qin L, Liu G, et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol diabetes. 2012;120(09):553–9.
68. Pernicova I, Akinci B, Prasai M, Baxter P, Scott E. Association between rs1801260 of the circadian gene CLOCK and lipid and glucose metabolism in women with Polycystic Ovary Syndrome. In: Society for Endocrinology BES 2012. BioScientifica; 2012.
69. Zhang J, Liu J, Zhu K, Hong Y, Sun Y, Zhao X, et al. Effects of BMAL1–SIRT1-positive cycle on estrogen synthesis in human ovarian granulosa cells: an implicative role of BMAL1 in PCOS. Endocrine. 2016;53(2):574–84.
70. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005 May;308(5724):1043–5.
71. Lamia KA, Papp SJ, Ruth TY, Barish GD, Uhlenhaut NH, Jonker JW, et al. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature. 2011;480(7378):552.
72. Lamia KA, Storch K-F, Weitz CJ. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci. 2008;105(39):15172–7.
73. Rudic RD, McNamara P, Curtis A-M, Boston RC, Panda S, Hogenesch JB, et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol. 2004;2(11):e377.
74. Shi S, Ansari TS, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol. 2013;23(5):372–81.
75. Shimizu T, Hirai Y, Murayama C, Miyamoto A, Miyazaki H, Miyazaki K. Circadian Clock genes Per2 and clock regulate steroid production, cell proliferation, and luteinizing hormone receptor transcription in ovarian granulosa cells. Biochem Biophys Res Commun. 2011;412(1):132–5.
76. Mead EJ, Maguire JJ, Kuc RE, Davenport AP. Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system. Br J Pharmacol. 2007 Aug;151(8):1143–53.
77. Nejad SZ, Tehrani FR, Zadeh-Vakili A. The role of kisspeptin in female reproduction. Int J Endocrinol Metab. 2017;15(3).
78. Gorkem U, Togrul C, Arslan E, Sargin Oruc A, Buyukkayaci Duman N. Is there a role for kisspeptin in pathogenesis of polycystic ovary syndrome? Gynecol Endocrinol. 2018;34(2):157–60.
79. Maganhin CC, Simões RS, Fuchs LFP, Sasso GRS, Simões MJ, Baracat EC, et al. Melatonin influences on steroidogenic gene expression in the ovary of pinealectomized rats. Fertil Steril. 2014;102(1):291–8.
80. Li C, Shi Y, You L, Wang L, Chen Z-J. Association of rs10830963 and rs10830962 SNPs in the melatonin receptor (MTNR1B) gene among Han Chinese women with polycystic ovary syndrome. MHR Basic Sci Reprod Med. 2011 Mar;17(3):193–8.
81. Li C, Shi Y, You L, Wang L, Chen ZJ. Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome. Gynecol Obstet Invest. 2011;72(2):130–4.
82. Hastings MH, Reddy AB, Maywood ES. A clockwork web: Circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci. 2003;4(8):649–61.
83. Hughes ME, DiTacchio L, Hayes KR, Vollmers C, Pulivarthy S, Baggs JE, et al. Harmonics of circadian gene transcription in mammals. PLoS Genet. 2009;5(4).
84. Trombly DJ, Woodruff TK, Ph D, Mayo KE. Role for Transforming Growth Factor Beta Superfamily Proteins in Early Folliculogenesis. Semin Reprod Med. 2009;27(1):14–23.
85. Espey LL, Richards JS. Temporal and Spatial Patterns of Ovarian Gene Transcription Following an Ovulatory Dose of Gonadotropin in the Rat1. Biol Reprod. 2002 Dec;67(6):1662–70.
86. Richards JS, Russell DL, Ochsner S, Espey LL. Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol. 2002;64(1):69–92.
87. Morris JK, Richards JS. An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells. J Biol Chem. 1996;271(28):16633–43.
88. Liu J, Antaya M, Boerboom D, Lussier JG, Silversides DW, Sirois J. The delayed activation of the prostaglandin G/H synthase-2 promoter in bovine granulosa cells is associated with down-regulation of truncated upstream stimulatory factor-2. J Biol Chem. 1999;274(49):35037–45.
89. Ratajczak CK, Boehle KL, Muglia LJ. Impaired steroidogenesis and implantation failure in Bmal1−/− mice. Endocrinology. 2008;150(4):1879–85.
90. Alvarez J, Hansen A, Ord T, Bebas P, Chappell PE, Giebultowicz JM, et al. The circadian clock protein BMAL1 is necessary for fertility and proper testosterone production in mice. J Biol Rhythms. 2008;23(1):26–36.
91. He P-J, Hirata M, Yamauchi N, Hashimoto S, Hattori M. Gonadotropic regulation of circadian clockwork in rat granulosa cells. Mol Cell Biochem. 2007;302(1–2):111–8.
92. Sellix MT, Yoshikawa T, Menaker M. A circadian egg timer gates ovulation. Curr Biol. 2010;20(6):R266–7.
93. Chen M, Xu Y, Miao B, Zhao H, Luo L, Shi H, et al. Expression pattern of circadian genes and steroidogenesis-related genes after testosterone stimulation in the human ovary. J Ovarian Res. 2016;9(1):1–7.
94. Lee B, Li A, Hansen KF, Cao R, Yoon JH, Obrietan K. CREB Influences Timing and Entrainment of the SCN Circadian Clock. J Biol Rhythms. 2010 Dec;25(6):410–20.
95. Ramos-Lopez O, Samblas M, Milagro FI, Riezu-Boj JI, Crujeiras AB, Martinez JA, et al. Circadian gene methylation profiles are associated with obesity, metabolic disturbances and carbohydrate intake. Chronobiol Int. 2018;00(00):1–13.
96. Fernandez R, Moore V, Van Ryswyk E, Varcoe T, Rodgers R, March W, et al. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Nat Sci Sleep. 2018;Volume 10:45–64.
97. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Metab. 2001;281(2):E392–9.
98. Vollmers C, Schmitz RJ, Nathanson J, Yeo G, Ecker JR, Panda S. Circadian oscillations of protein-coding and regulatory RNAs in a highly dynamic mammalian liver epigenome. Cell Metab. 2012 Dec;16(6):833–45.
99. Etchegaray J-P, Lee C, Wade PA, Reppert SM. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature. 2003 Jan;421(6919):177–82.
100. Fogg PCM, O’Neill JS, Dobrzycki T, Calvert S, Lord EC, McIntosh RLL, et al. Class IIa histone deacetylases are conserved regulators of circadian function. J Biol Chem. 2014;289(49):34341–8.
101. Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, Melatonin and Circadian Rhythms: Building a Bridge between Aging and Cancer. Vol. 48, Journal of pineal research. 2010. p. 9–19.
102. Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, Kreppel F, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell. 2008 Jul;134(2):317–28.
103. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, et al. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell. 2008 Jul;134(2):329–40.
104. Masri S. Sirtuin-Dependent Clock Control: New Advances in Metabolism, Aging and Cancer. Vol. 18, Current opinion in clinical nutrition and metabolic care. 2015. p. 521–7.
105. Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med. 2011;43(3):198–211.
106. Martins I, Wilson A, Lim WL, Laws S, Fuller S, Martins R. Sirtuin-1 mediates the obesity induced risk of common degenerative diseases: Alzheimer’s disease, coronary artery disease and type 2 diabetes. 2012;
107. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–36.
108. Kiyak Caglayan E, Engin-Ustun Y, Gocmen AY, Polat MF, Aktulay A. Serum sirtuin 1 levels in patients with polycystic ovary syndrome. J Obstet Gynaecol. 2015;35(6):608–11.
109. Ma X, Hayes E, Biswas A, Seger C, Prizant H, Hammes SR, et al. Androgens Regulate Ovarian Gene Expression Through Modulation of Ezh2 Expression and Activity. Vol. 158, Endocrinology. 2017. p. 2944–54.
110. Hansen KF, Sakamoto K, Obrietan K. MicroRNAs: A potential interface between the circadian clock and human health. Genome Med. 2011;3(2):1–8.
111. Cheng HYM, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, et al. microRNA Modulation of Circadian-Clock Period and Entrainment. Neuron. 2007;54(5):813–29.
112. Cheng HYM, Obrietan K. Revealing a role of microRNAs in the regulation of the biological clock. Cell Cycle. 2007;6(24):3034–8.
113. Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, Cornejo-Palma D, Perez-Iratxeta C, et al. miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum Mol Genet. 2011;20(4):731–51.
114. Figueredo DDS, Barbosa MR, Gitaí DLG, De Andrade TG. Predicted microRNAs for mammalian circadian rhythms. J Biol Rhythms. 2013;28(2):107–16.
115. Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet. 2001;27(2):159.
116. Uhlenhaut NH, Jakob S, Anlag K, Eisenberger T, Sekido R, Kress J, et al. Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation. Cell. 2009;139(6):1130–42.
117. Kochan DZ, Ilnytskyy Y, Golubov A, Deibel SH, McDonald RJ, Kovalchuk O. Circadian disruption-induced microRNAome deregulation in rat mammary gland tissues. Oncoscience. 2015;2(4):428–42.
118. Long W, Zhao C, Ji C, Ding H, Cui Y, Guo X, et al. Characterization of Serum MicroRNAs Profile of PCOS and Identification of Novel Non-Invasive Biomarkers. Cell Physiol Biochem. 2014;33(5):1304–15.
119. Hong Z, Feng Z, Sai Z, Tao S. PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer In vitro. BMB Rep. 2014;47(9):500–5.
120. Sørensen AE, Wissing ML, Englund ALM, Dalgaard LT. MicroRNA species in follicular fluid associating with polycystic ovary syndrome and related intermediary phenotypes. J Clin Endocrinol Metab. 2016;101(4):1579–89.
121. Yoo S-H, Kojima S, Shimomura K, Koike N, Buhr ED, Furukawa T, et al. Period2 3′-UTR and microRNA-24 regulate circadian rhythms by repressing PERIOD2 protein accumulation. Proc Natl Acad Sci. 2017;201706611.
122. Rongmin Chen, Matthew D’Alessandro and CL. miRNAs are required for generating a time-delay critical for the circadian oscillator. Curr Biol. 2014;23(20).
123. Sirotkin A V, Ovcharenko D, Grossmann R, Laukova M, Mlyncek M. Identification of microRNAs controlling human ovarian cell steroidogenesis via a genome-scale screen. J Cell Physiol. 2009 May;219(2):415–20.
124. Murri M, Insenser M, Fernandez-Duran E, San-Millan JL, Escobar-Morreale HF. Effects of polycystic ovary syndrome (PCOS), sex hormones, and obesity on circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 expression. J Clin Endocrinol Metab. 2013 Nov;98(11):E1835-44.
125. Wazen RM, Kuroda S, Nishio C, Sellin K, Brunski JB, Nanci A. Gene expression profiling and histomorphometric analyses of the early bone healing response around nanotextured implants. Nanomedicine. 2013;8(9):1385–95.